Bharat Serums and Vaccines Limited

Gautam Vinod Daftary

Sangeeta Hanurmesh Rivankar

Vasanthan Mani

Srikanth Annappa Pai

Suresh Kumar Natarajan

Cyril Fernandez Lourdnathan Joseph

Girish Narasimha Shanbhag

John Kaundinya

Tomas Cinek

Praveen Kumar Subbappa

Cyril Fernandez Joseph

Mangesh Manikrao Kulkarni

A safety housing based implant/medicament injecting system. The system includes a needle assembly prefilled with an implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage-wise forward motion including an initial-injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and a subsequent continuing-injecting plunger forward motion independent of the needle assembly for injecting the implant/medicament. The needle assembly configured to return post-injecting to be secured inside said housing blocking any subsequent use thereof.

Safety housing based implant/medicament injecting system

A safety housing based implant/medicament injecting system. System includes a needle assembly prefilled implant/medicament for injection and an injecting needle/cannula, a housing for accommodating the needle assembly under usual bias inside said housing, a plunger means having a plunger rod configured for stage wise forward motion including an initial injecting plunger forward motion with the needle assembly within the housing to first engage the needle assembly with the housing and subsequent continuing injecting plunger forward motion independent of the needle assembly for injecting of the implant/medicament, and post injecting return of the needle assembly secured inside said housing blocking any subsequent use thereof.

Safety housing based implant/ medicament injecting system

The present invention provides a long circulating non-pegylated liposomal doxorubicin hydrochloride composition for parenteral administration and a process for its preparation. The circulation time in Swiss albino mice is at least 25 times longer than conventional non-liposomal formulations. The non-pegylated liposomes are stable, exhibit low toxicity and have been found to be efficacious in different tumor models.

Non-pegylated long-circulating liposomes

The invention discloses a stable intravenous Propofol oil-in-water emulsion composition having mixed preservatives of low toxicity that is capable of withstanding accidental contamination of bacteria and fungi. The preservative system employed comprising of monoglyceryl ester of lauric acid (Monolaurin) and a member selected from (a) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin); (b) edetate; and (c) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin) and edetate.

Intravenous propofol emulsion compositions having preservative efficacy

Anti-RhD monoclonal antibodies and methods for the production thereof.

Anti-RhD monoclonal antibodies

The present invention provides aqueous Ifosfamide compositions and a process for their preparation, in which the compositions have a reduced toxicity over and above the concomitant use of the uroprotective agent, Mesna. Aqueous Ifosfamide compositions can be prepared at concentrations as high has 1,1000 mg/ml.

Growing community of inventors

Mumbai, India

Gautam Vinod Daftary